A5210: PHASE IB/IIA DOSE-FINDING SAFETY AND ACTIVITY STUDY OF AMD11070

A5210：AMD11070 的 IB/IIA 期剂量探索安全性和活性研究

• 批准号: 7603601
• 负责人: Jeffrey Lennox
• 金额: $ 1.38万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-12-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7603601
• 关键词: Computer Retrieval of Information on Scientific Projects Database; Dose; Funding; Grant; Institution; Phase; Research; Research Personnel; Resources; Safety; Source; United States National Institutes of Health; Virus; cohort; day

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary objectives of this study are to determine the safety of several dose levels of AMD11070 (with the starting dose determined by the results of A5191 administered over 10 days with HIV-infected subjects who harbor X4-tropic virus and to determine the proportion of subjects per cohort who have a ?1 log10 rlu reduction in X4-tropic virus during 10 days of AMD11070 treatment or in the 7 days following treatment discontinuation, and to describe changes from baseline to day 10 in log10 rlu corresponding to X4-tropic virus

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 这项研究的主要目的是确定几个剂量水平的AMD11070的安全性（起始剂量由10天的A5191的结果确定，这些受试者在10天内施用了X4循环病毒的HIV感染受试者，并确定在X4-luu降低X4-luu降低X4-trupic and AMD AMD的比例，并在X4-luu降低后，在X4-luu降低后10天。中断，并描述从基线到log10 rlu的第10天的变化，与X4-Tropic病毒相对应